RAPP (Rapport Therapeutics, Inc.) Short-Term Debt to Capital
The current market quotes for Rapport Therapeutics, Inc. (RAPP) visualized below on GURU.Markets show the metric at 0.00. The business relies on a unique neurobiological system that creates exclusive therapies by targeting brain proteins. Management aims to transform care for epilepsy patients by implementing a precision approach. Drug development strictly adheres to FDA regulations, ensuring high customer loyalty through safety.
Analytical breakdowns for Rapport Therapeutics, Inc.
This indicator measures equity resilience to credit shocks via the ratio of liabilities with maturities exceeding one year to net capital, determining the issuer's margin of safety in the event that loans cannot be refinanced. By analyzing the history of short-term debt to equity, an investor assesses the financial flexibility of Rapport Therapeutics, Inc. (RAPP), which is critically important when delegating clinical trials and production to external contractors.